Why most pharma transformations stall, and how to be in the few that do not

Most digital transformations in pharma stall for reasons that have nothing to do with technology. The platforms work. The integrators are competent. The business cases are real. After two decades leading these programmes inside global quality and IT organisations, I have watched the same four failure patterns repeat across companies that share nothing except an org chart shape, and I have watched a smaller set of habits separate the programmes that deliver.

The four ways programmes stall

The first is governance built for projects rather than change. A transformation is run like a system rollout: a steering committee that reviews milestones but cannot retire a legacy process, kill a duplicate tool, or overrule a site that wants its exception. Milestones get greener while the operating model stays untouched.

The second is validation treated as the tax at the end. Quality and validation leaders meet the programme at the gate, late, with no stake in its design. The result is predictable: the new digital process gets wrapped in the old paper assurance, the savings evaporate into protocols, and the organisation concludes that compliance and speed are enemies. They are only enemies when one of them is designed last.

The third is automation aimed at the interesting work instead of the boring work. Demos reward novelty, so programmes automate judgment, which fails, instead of automating assembly, routing and transcription, which is where the hours actually live. Credibility dies in the gap.

The fourth is change management funded last and cut first. The SOP rewrites, the role redesign, the training time, the months of floor support: this is the actual transformation. The software is just its occasion.

What the few do differently

The programmes that work share habits more than budgets. They redesign the process before configuring the platform, so the new system never inherits the old mess. They put quality at the design table with a mandate to modernise assurance itself, which is what the move from CSV to CSA makes possible: effort following risk instead of habit. They sequence for visible wins in the highest-volume flows, and they measure honestly: cycle time, hours per record, retrieval time, before and after. They keep one governed template across sites, with local deltas controlled rather than negotiated. And they treat the first inspection of the new way of working as a design goal from day one, because surviving that inspection is what converts a project into the new normal.

On programmes built this way I have seen paperless validation remove around six million paper records a year across 40-plus sites, validation cycles run 65 percent faster, and inspection findings stay at zero through the whole rollout. The difference was never the platform. It was who held the pen during design, and what the steering committee was allowed to decide.

The Monday question

If your transformation is two years in and the metrics have not moved, ask one question first: can your steering committee retire a process? If the answer is no, you do not have a transformation. You have a procurement with ambitions, and the fix starts with governance, not with another platform.

Sachin Bhandari advises pharma, biotech, medical device and CDMO organisations on AI in GxP, CSV to CSA and digital validation. The frameworks behind this essay are on the frameworks page, free to download. If a programme of yours is stalling, start with Digital Quality and QMS and the QMS 2.0 framework.